b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">29113740</PMID>\n        <DateCompleted>\n            <Year>2018</Year>\n            <Month>06</Month>\n            <Day>21</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>01</Month>\n            <Day>07</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1872-9096</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>149</Volume>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>01</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Antiviral research</Title>\n                <ISOAbbreviation>Antiviral Res.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1-6</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S0166-3542(17)30621-6</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2017.11.002</ELocationID>\n            <Abstract>\n                <AbstractText>Pritelivir, a helicase-primase inhibitor, has excellent in vitro and in vivo activity against human herpes simplex virus (HSV). Mice lethally infected with HSV type 1 or 2, including acyclovir-resistant strains, were treated 72\xc2\xa0h after infection for 7 days with pritelivir or acyclovir. Both drugs were administered orally twice daily either alone or in combination. Dosages of pritelivir from 0.3 to 30\xc2\xa0mg/kg reduced mortality (P\xc2\xa0&lt;\xc2\xa00.001) against HSV-1, E-377. With an acyclovir resistant HSV-1, 11360, pritelivir at 1 and 3\xc2\xa0mg/kg increased survival (P\xc2\xa0&lt;\xc2\xa00.005). With HSV-2, MS infected mice, all dosages higher than the 0.3\xc2\xa0mg/kg dose of pritelivir were effective (P\xc2\xa0&lt;\xc2\xa00.005). For acyclovir resistant HSV-2, strain 12247, pritelivir dosages of 1-3\xc2\xa0mg/kg significantly improved survival (P\xc2\xa0&lt;\xc2\xa00.0001). Combination therapies of pritelivir at 0.1 or 0.3\xc2\xa0mg/kg/dose with acyclovir (10\xc2\xa0mg/kg/dose) were protective (P\xc2\xa0&lt;\xc2\xa00.0001) when compared to the vehicle treated group against HSV-2, strain MS (in line with previous data using HSV-1). An increased mean days to death (P\xc2\xa0&lt;\xc2\xa00.05) was also observed and was indicative of a potential synergy. Pharmacokinetic studies were performed to determine pritelivir concentrations and a dose dependent relationship was found in both plasma and brain samples regardless of infection status or time of initiation of dosing. In summary, pritelivir was shown to be active when treatment was delayed to 72\xc2\xa0h post viral inoculation and appeared to synergistically inhibit mortality in this model in combination with acyclovir. We conclude pritelivir has potent and resistance-breaking antiviral efficacy with potential for the treatment of potentially life-threatening HSV type 1 and 2 infections, including herpes simplex encephalitis.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2017 Elsevier B.V. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Quenelle</LastName>\n                    <ForeName>Debra C</ForeName>\n                    <Initials>DC</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>The University of Alabama at Birmingham, School of Medicine, Birmingham, AL, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Birkmann</LastName>\n                    <ForeName>Alexander</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>AiCuris Anti-Infective Cures GmbH, Wuppertal, Germany. Electronic address: alexander.birkmann@aicuris.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Goldner</LastName>\n                    <ForeName>Thomas</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>AiCuris Anti-Infective Cures GmbH, Wuppertal, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Pfaff</LastName>\n                    <ForeName>Tamara</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>AiCuris Anti-Infective Cures GmbH, Wuppertal, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zimmermann</LastName>\n                    <ForeName>Holger</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>AiCuris Anti-Infective Cures GmbH, Wuppertal, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bonsmann</LastName>\n                    <ForeName>Susanne</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>AiCuris Anti-Infective Cures GmbH, Wuppertal, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Collins</LastName>\n                    <ForeName>Deborah J</ForeName>\n                    <Initials>DJ</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>The University of Alabama at Birmingham, School of Medicine, Birmingham, AL, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Rice</LastName>\n                    <ForeName>Terri L</ForeName>\n                    <Initials>TL</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>The University of Alabama at Birmingham, School of Medicine, Birmingham, AL, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Prichard</LastName>\n                    <ForeName>Mark N</ForeName>\n                    <Initials>MN</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>The University of Alabama at Birmingham, School of Medicine, Birmingham, AL, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>N01AI15439</GrantID>\n                    <Acronym>AI</Acronym>\n                    <Agency>NIAID NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2017</Year>\n                <Month>11</Month>\n                <Day>04</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Netherlands</Country>\n            <MedlineTA>Antiviral Res</MedlineTA>\n            <NlmUniqueID>8109699</NlmUniqueID>\n            <ISSNLinking>0166-3542</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>07HQ1TJ4JE</RegistryNumber>\n                <NameOfSubstance UI="C453221">pritelivir</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>X4HES1O11F</RegistryNumber>\n                <NameOfSubstance UI="D000212">Acyclovir</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000212" MajorTopicYN="N">Acyclovir</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D020803" MajorTopicYN="N">Encephalitis, Herpes Simplex</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n                <QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Antiviral therapy</Keyword>\n            <Keyword MajorTopicYN="Y">Combination</Keyword>\n            <Keyword MajorTopicYN="Y">Efficacy</Keyword>\n            <Keyword MajorTopicYN="Y">Herpes simplex encephalitis</Keyword>\n            <Keyword MajorTopicYN="Y">Murine model</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2017</Year>\n                <Month>09</Month>\n                <Day>05</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2017</Year>\n                <Month>10</Month>\n                <Day>27</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2017</Year>\n                <Month>11</Month>\n                <Day>03</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2017</Year>\n                <Month>11</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2018</Year>\n                <Month>6</Month>\n                <Day>22</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2017</Year>\n                <Month>11</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29113740</ArticleId>\n            <ArticleId IdType="pii">S0166-3542(17)30621-6</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.antiviral.2017.11.002</ArticleId>\n            <ArticleId IdType="pmc">PMC5743594</ArticleId>\n            <ArticleId IdType="mid">NIHMS919751</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Antiviral Res. 2014 Nov;111:36-41</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25218782</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2014 Jan 16;370(3):201-10</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24428466</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Med Mal Infect. 2017 May;47(3):221-235</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28341533</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Antimicrob Agents Chemother. 2009 Dec;53(12):5251-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19770274</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Virol. 2014 Nov;61(3):382-6</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25204613</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>JAMA. 2016 Dec 20;316(23 ):2495-2503</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27997653</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Med. 2002 Apr;8(4):392-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11927946</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Antimicrob Agents Chemother. 2011 Oct;55(10):4728-34</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21788472</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Antiviral Res. 2006 Sep;71(2-3):141-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16675036</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Continuum (Minneap Minn). 2015 Dec;21(6 Neuroinfectious Disease):1704-13</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26633784</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Microbiol. 2013 Jan;51(1):356-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23100343</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Antimicrob Agents Chemother. 2007 Nov;51(11):4118-24</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">17724153</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Virol. 2014 Jan;59(1):67-70</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24257111</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Antimicrob Agents Chemother. 2013 Aug;57(8):3518-27</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23669381</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Antiviral Res. 2013 Nov;100(2):365-72</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24075863</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Infect Dis. 2016 Jul 15;214(2):258-64</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27056950</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Perinatol. 2015 Mar;42(1):47-59, viii</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25677996</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Neurovirol. 2017 Apr;23 (2):335-337</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27787806</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Antimicrob Agents Chemother. 2002 Jun;46(6):1766-72</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">12019088</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Curr Opin Infect Dis. 2016 Dec;29(6):654-662</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27306564</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'